Related Experiment Videos
Treatment effect modifiers for the patient education programme for Parkinson's disease
L E I A'Campo1, E M Wekking, N G A Spliethoff-Kamminga
1Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands. L.E.I.A_Campo@lumc.nl
International Journal of Clinical Practice
|December 17, 2011
Summary
For Parkinson's disease (PD) caregivers, patients' higher baseline cognitive function predicted less caregiver burden after the Patient Education Programme for Parkinson's disease (PEPP). No patient-specific treatment effect modifiers were identified.
Area of Science:
- Neuroscience
- Psychology
- Gerontology
Background:
- A randomized controlled trial of the Patient Education Programme for Parkinson's disease (PEPP) demonstrated significant benefits for caregivers' psychosocial well-being and a trend toward improved patient quality of life.
- Variability in treatment outcomes suggests the presence of effect modifiers that influence the PEPP's efficacy.
Purpose of the Study:
- To identify patient and caregiver characteristics that modify the treatment effects of the PEPP.
- To explore factors influencing the outcomes of Parkinson's disease (PD) patients and their caregivers participating in an educational intervention.
Main Methods:
- Secondary analysis of a randomized controlled trial involving 64 PD patients and 46 caregivers.
- Regression analyses were used to examine treatment effect modifiers, including participant demographics, baseline psychological scores (BELA-P/A-k, PDQ-39, EQ-5D, Self-rating Depression Scale), and patient neuropsychological test results (MMSE, NART, Word Test, E-S, TMT, Stroop).
- Outcome measures included patient quality of life (PDQ-39) and caregiver psychosocial burden (BELA-A-k).
Main Results:
- No significant treatment effect modifiers were identified for PD patients regarding demographics, disease stage, cognitive function, or baseline psychosocial burden.
- For caregivers, higher baseline Mini Mental State Examination (MMSE) scores in PD patients significantly predicted lower caregiver-reported burden (BELA-A-k Bothered by score) post-intervention.
Conclusions:
- Patient cognitive functioning, specifically higher MMSE scores, may predict greater treatment benefit for caregivers in the PEPP intervention.
- The PEPP appears to be a broadly applicable intervention for most PD patients, as no significant patient-specific treatment effect modifiers were found.
- Further research could explore the mechanisms linking patient cognition to caregiver outcomes in PD interventions.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...